Liver Treatment Company Galmed is Raising $6 Million in Direct Offering
The company’s stock fell by 37% on Nasdaq since the beginning of the year, and by 66% since its Nasdaq listing in 2014
For daily updates, subscribe to our newsletter by clicking here.
Galmed is a clinical-stage company developing once-daily oral therapy for liver diseases. The company’s product, Aramchol, is currently in advanced clinical trials. It has been granted fast track designation status by the U.S. Food and Drug Administration for the treatment of nonalcoholic steatohepatitis (NASH), a progressive type of fatty liver disease that includes inflammation, tissue scarring, and reduced liver function.